Search

Your search keyword '"Kay, Neil E."' showing total 37 results
Start Over Author "Kay, Neil E." Journal leukemia & lymphoma
37 results on '"Kay, Neil E."'

2. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

Author

Bantilan, Kurt S., primary, Kay, Neil E., additional, Parikh, Sameer A., additional, Rabe, Kari G., additional, Call, Timothy G., additional, Leis, Jose F., additional, Ding, Wei, additional, Slager, Susan L., additional, Soumerai, Jacob D., additional, Roeker, Lindsey E., additional, Mato, Anthony, additional, and Zelenetz, Andrew D., additional

Published
2022
Full Text
View/download PDF

3. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.

Author

Bantilan, Kurt S., Kay, Neil E., Parikh, Sameer A., Rabe, Kari G., Call, Timothy G., Leis, Jose F., Ding, Wei, Slager, Susan L., Soumerai, Jacob D., Roeker, Lindsey E., Mato, Anthony, and Zelenetz, Andrew D.

Subjects
*CHRONIC lymphocytic leukemia, *OVERALL survival, *DISEASE risk factors, *FOLLICULAR lymphoma, *CHRONIC leukemia, *PROGNOSTIC models
Abstract

Targeted therapies have largely replaced chemoimmunotherapy (CIT) in first-line treatment of chronic lymphocytic leukemia (CLL). We aimed to develop a prognostic model to determine who would benefit from first-line CIT vs target therapy. In follicular lymphoma, time from diagnosis to second treatment (TT2T) correlates better with overall survival (OS) than time from diagnosis to first treatment (TT1T). We hypothesized that TT2T is a potential surrogate for OS in CLL. In a model-building cohort (n = 298), we evaluated potential predictors for TT2T and derived a risk score, which we validated in an external cohort (n = 1141). Our data demonstrated that TT2T and OS were more strongly correlated than TT1T and OS. Our risk score model consisted of three predictors (unmutated IGHV, β2-microglobulin >297 nmol/L, and Rai stage I–IV), and was prognostic for TT2T and OS. TT2T is a promising surrogate for OS in CLL, but further validation is needed to establish this association. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice

Author

Koehler, Amber B., primary, Leung, Nelson, additional, Call, Timothy G., additional, Rabe, Kari G., additional, Achenbach, Sara J., additional, Ding, Wei, additional, Kenderian, Saad S., additional, Leis, Jose F., additional, Wang, Yucai, additional, Muchtar, Eli, additional, Hayman, Suzanne R., additional, Hampel, Paul J., additional, Finnes, Heidi D., additional, Schwager, Susan M., additional, Slager, Susan L., additional, Kay, Neil E., additional, and Parikh, Sameer A., additional

Published
2020
Full Text
View/download PDF

5. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

Author

Hampel, Paul J., primary, Ding, Wei, additional, Call, Timothy G., additional, Rabe, Kari G., additional, Kenderian, Saad S., additional, Witzig, Thomas E., additional, Muchtar, Eli, additional, Leis, Jose F., additional, Chanan-Khan, Asher A., additional, Koehler, Amber B., additional, Fonder, Amie L., additional, Schwager, Susan M., additional, Slager, Susan L., additional, Shanafelt, Tait D., additional, Kay, Neil E., additional, and Parikh, Sameer A., additional

Published
2019
Full Text
View/download PDF

6. Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect®CLL cohort study

Author

Flowers, Christopher R., primary, Nabhan, Chadi, additional, Kay, Neil E., additional, Mato, Anthony, additional, Lamanna, Nicole, additional, Farber, Charles M., additional, Davids, Matthew S., additional, Kiselev, Pavel, additional, Swern, Arlene S., additional, Sullivan, Kristen, additional, Flick, E. Dawn, additional, and Sharman, Jeff P., additional

Published
2018
Full Text
View/download PDF

7. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Author

Shanafelt, Tait D., primary, Parikh, Sameer A., additional, Noseworthy, Peter A., additional, Goede, Valentin, additional, Chaffee, Kari G., additional, Bahlo, Jasmin, additional, Call, Timothy G., additional, Schwager, Susan M., additional, Ding, Wei, additional, Eichhorst, Barbara, additional, Fischer, Kirsten, additional, Leis, Jose F., additional, Chanan-Khan, Asher Alban, additional, Hallek, Michael, additional, Slager, Susan L., additional, and Kay, Neil E., additional

Published
2016
Full Text
View/download PDF

8. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

Author

Finnes, Heidi D., primary, Chaffee, Kari G., additional, Call, Timothy G., additional, Ding, Wei, additional, Kenderian, Saad S., additional, Bowen, Deborah A., additional, Conte, Michael, additional, McCullough, Kristen B., additional, Merten, Julianna A., additional, Bartoo, Gabriel T., additional, Smith, Matthew D., additional, Leis, Jose, additional, Chanan-Khan, Asher, additional, Schwager, Susan M., additional, Slager, Susan L., additional, Kay, Neil E., additional, Shanafelt, Tait D., additional, and Parikh, Sameer A., additional

Published
2016
Full Text
View/download PDF

10. Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study.

Author

Flowers, Christopher R., Nabhan, Chadi, Kay, Neil E., Mato, Anthony, Lamanna, Nicole, Farber, Charles M., Davids, Matthew S., Kiselev, Pavel, Swern, Arlene S., Sullivan, Kristen, Flick, E. Dawn, and Sharman, Jeff P.

Subjects
CHRONIC lymphocytic leukemia, COHORT analysis, CYTOGENETICS, CYTOLOGY, LYMPHOCYTOSIS
Abstract

A 'watch-and-wait' strategy is recommended for most patients with early-stage chronic lymphocytic leukemia (CLL) prior to treatment initiation. In the Connect® CLL registry, a prospective observational cohort study of 1494 patients treated in 199 US centers, median time to first-line treatment initiation was 3.8, 1.5, and 0.6 years for patients with Rai stage 0, 1, and ≥2, respectively. Only 60% of patients with Rai stage 0/1 underwent FISH/cytogenetic testing prior to initiation of a new line of therapy. Lymphocytosis and lymphadenopathy were the most common reasons for treatment initiation. Lymphocytosis as a reason for treatment initiation was associated with inferior event-free survival at Rai stage 0/1. Short treatment duration was associated with inferior overall survival regardless of Rai stage; sensitivity analyses confirmed the association. The Connect CLL registry provides valuable information on a real-world population of patients with CLL, clarifying both the timing and rationale for initiating therapy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

11. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).

Author

Shanafelt, Tait D., Parikh, Sameer A., Noseworthy, Peter A., Goede, Valentin, Chaffee, Kari G., Bahlo, Jasmin, Call, Timothy G., Schwager, Susan M., Ding, Wei, Eichhorst, Barbara, Fischer, Kirsten, Leis, Jose F., Chanan-Khan, Asher Alban, Hallek, Michael, Slager, Susan L., and Kay, Neil E.

Subjects
ATRIAL fibrillation, CHRONIC lymphocytic leukemia, DISEASE incidence, MULTIVARIATE analysis, HYPERTENSION
Abstract

Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p < .0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

12. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

Author

Finnes, Heidi D., Chaffee, Kari G., Call, Timothy G., Ding, Wei, Kenderian, Saad S., Bowen, Deborah A., Conte, Michael, McCullough, Kristen B., Merten, Julianna A., Bartoo, Gabriel T., Smith, Matthew D., Leis, Jose, Chanan-Khan, Asher, Schwager, Susan M., Slager, Susan L., Kay, Neil E., Shanafelt, Tait D., and Parikh, Sameer A.

Subjects
CHRONIC lymphocytic leukemia treatment, LYMPHOMA treatment, CYTOCHROME P-450, CLINICAL trials, DRUG toxicity, DRUG efficacy
Abstract

Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%) patients were on medications that could increase ibrutinib toxicity and 4 (3%) were on drugs that could decrease ibrutinib efficacy. Nineteen (16%) patients were on concomitant CYP3A inhibitors (11 moderate, 8 strong), and 4 (3%) were on CYP3A inducers (two patients were on both CYP3A inhibitors and inducers). Although the ibrutinib starting dose was changed in 18 patients on CYP3A interacting medications, no difference in 18-month progression-free survival or rate of ibrutinib discontinuation was observed in patients who were not. In routine clinical practice, 2 of 3 CLL patients commencing ibrutinib are on a concomitant medication with potential to influence ibrutinib metabolism. Formal medication review by a pharmacist should be considered in all patients initiating ibrutinib. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

15. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

Author

Zent, Clive S., primary, Smith, Brian J., additional, Ballas, Zuhair K., additional, Wooldridge, James E., additional, Link, Brian K., additional, Call, Timothy G., additional, Shanafelt, Tait D., additional, Bowen, Deborah A., additional, Kay, Neil E., additional, Witzig, Thomas E., additional, and Weiner, George J., additional

Published
2011
Full Text
View/download PDF

20. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis

Author

Zent, Clive S., primary, Ding, Wei, additional, Reinalda, Megan S., additional, Schwager, Susan M., additional, Hoyer, James D., additional, Bowen, Deborah A., additional, Jelinek, Diane F., additional, Tschumper, Renee C., additional, Call, Timothy G., additional, Shanafelt, Tait D., additional, Kay, Neil E., additional, and Slager, Susan L., additional

Published
2009
Full Text
View/download PDF

30. Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Author

Zent, Clive S., Wu, Wenting, Bowen, Deborah A., Hanson, Curtis A., Pettinger, Adam M., Shanafelt, Tait D., Kay, Neil E., Leis, Jose F., and Call, Timothy G.

Subjects
CHRONIC lymphocytic leukemia, ALEMTUZUMAB, RITUXIMAB, COLONY-stimulating factors (Physiology), TREATMENT effectiveness, CANCER risk factors
Abstract

Thirty-three previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) were treated before meeting standard criteria with alemtuzumab and rituximab. Granulocyte macrophage colony stimulating factor (GM-CSF) was added to the regimen to determine whether it would improve treatment efficacy without increasing toxicity. High risk was defined as at least one of the following: 17p13−; 11q22.3−; unmutated IGHV (or use of VH3-21) together with elevated expression of ZAP-70 and/or CD38. Treatment was subcutaneous GM-CSF 250 μg Monday-Wednesday-Friday for 6 weeks from day 1, subcutaneous alemtuzumab 3 mg-10 mg-30 mg from day 3 and then 30 mg Monday-Wednesday-Friday for 4 weeks, and intravenous rituximab (375 mg/m2/week) for 4 weeks from day 8. Patients received standard supportive care and were monitored weekly for cytomegalovirus (CMV) reactivation. Using standard criteria, 31 (94%) patients responded to treatment, with nine (27%) complete responses (one with persistent cytopenia) and nine (27%) nodular partial responses. Median progression-free survival was 13.0 months and time to next treatment was 33.5 months. No patient died during treatment, seven (21%) had grade 3-4 toxicities attributable to treatment, and 10 (30%) had CMV viremia. Addition of GM-CSF to therapy with alemtuzumab and rituximab decreased treatment efficacy and increased the rate of CMV reactivation compared to a historical control. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

32. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.

Author

Zent, Clive S., Smith, Brian J., Ballas, Zuhair K., Wooldridge, James E., Link, Brian K., Call, Timothy G., Shanafelt, Tait D., Bowen, Deborah A., Kay, Neil E., Witzig, Thomas E., and Weiner, George J.

Subjects
CHRONIC lymphocytic leukemia, OLIGONUCLEOTIDES, B cells, DENDRITIC cells, LYMPHOCYTIC leukemia, CLINICAL trials
Abstract

CpG oligonucleotide 7909 (CpG 7909, PF-03512676), a synthetic 24mer single stranded agonist of TLR9 expressed by B cells and plasmacytoid dendritic cells, is immunomodulatory and can cause activation-induced death of chronic lymphocytic leukemia (CLL) cells. We report a phase I study of CpG 7909 in 41 patients with early relapsed CLL. A single intravenous dose of CpG 7909 was well tolerated with no clinical effects and no significant toxicity up to 1.05 mg/kg. Single dose subcutaneous CpG 7909 had a maximum tolerated dose (MTD) of 0.45 mg/kg with dose limiting toxicity of myalgia and constitutional effects. Multiple weekly subcutaneous doses at the MTD were well tolerated. CpG 7909 administration induced immunologic changes in CLL and non-malignant cells that were dose and route dependent. We conclude that multidose therapy with subcutaneous CpG 7909 (0.45 mg/kg) could be used in future phase II combination clinical trials for CLL. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

37. Malignant B Cell CD5 Membrane Phenotype and B Cell Colony Growth In Vivoand In Vitroin Patients with B-Chronic Lymphocytic Leukemia: Analysis with Clinical Parameters

Author

Hings, Ingrid, Kay, Neil E., Ranheim, Erik, Seroogy, Chris, and Parson, Robert E.

Abstract

Chronic lymphocytic leukemia (CLL), despite an overall good prognosis, has a subgroup of patients with more rapid, aggressive disease. In an attempt to generate additional information about the B cell clones in B-CLL which could be used as predictive parameters, we analysed CD5 membrane phenotype and B cell colony growth in 29 B-CLL patients. CD5, a 67-kd glycoprotein, has been reported to be a consistent feature of the malignant B cell membrane phenotype in CLL. We used an in vitroB cell colony assay to study the in vitrogrowth, differentiation, and cell surface properties of CLL B cells. Finally, a variety of standard clinical parameters were collated for each patient. Monoclonal antibodies to both CD5 and CD 19 (pan B cell marker) were used to perform 2-color flow cytometry on freshly purified CLL B cells and on CLL B cells harvested after 7 days of in vitroculture. We demonstrate here that CLL B cells are heterogeneous with respect to their expression of CD5, and that this expression is not fixed but may vary both in vivoand in vitro. In vitrogrowth potential, as measured by the B cell colony assay, was also heterogeneous with three subgroups defined as low growth (<10 colonies), intermediate (10-100 colonies) and high growth (>100 colonies). Furthermore a T cell conditioned medium was not found to be a requirement for in vitrocolony growth in the majority of CLL B cells. In addition, we evaluated the potential correlation of B cell CD5 phenotype or B cell colony growth on standard clinical parameters. A correlation between high CD5 expression (>85% CD5 positive) and lymphocyte doubling time less than 12 months and treatment within six months was detected. This study emphasizes that additional information regarding the biology of the malignant CLL B cell will generate new parameters that can be used to help predict the clinical course of B-CLL.

Published
1993
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results